Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free survival compared to Merck's Keytruda, despite showing numerically longer median survival with the high-dose combination. No new safety issues were found. The trial involved 1,546 patients with advanced melanoma and compared two dose levels of fianlimab plus cemiplimab against pembrolizumab. Meanwhile, Regeneron recently partnered with Telix Pharmaceuticals to develop new radiopharmaceutical therapies in oncology, aiming to strengthen their market position.
